NCT05675579 is a Phase 2 clinical trial of Sacituzumab Govitecan in Breast Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05675579?

NCT05675579 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05675579?

Interventions in NCT05675579: Sacituzumab Govitecan, Pembrolizumab.

What condition does NCT05675579 study?

NCT05675579 studies Breast Cancer.

Is NCT05675579 still recruiting?

NCT05675579 is currently active, enrolled. Last updated 4 November 2025.

Last reviewed 2025-11-04 · How we verify

NCT05675579

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Active, enrolled Phase 2 Last updated 4 November 2025

What this trial tests

Phase 2 trial testing Sacituzumab Govitecan in Breast Cancer in 27 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 May 2023

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	23 May 2023
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Sacituzumab Govitecan — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast cancer that has not responded well to other treatments.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Current and future immunotherapy for breast cancer.
Heater NK, Warrior S, Lu J. · · 2024 · cited 38× · PMID 39722028 · DOI 10.1186/s13045-024-01649-z
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions.
Tong Y, Fan X, Liu H, Liang T. · · 2024 · cited 20× · PMID 39555080 · DOI 10.3389/fimmu.2024.1495675
Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment.
Yang Y, Li H, Yang W, Shi Y. · · 2024 · cited 11× · PMID 39430759 · DOI 10.3389/fimmu.2024.1441667
Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs.
Jiang Y, Zhou H, Liu J, Ha W, et al · · 2024 · cited 11× · PMID 38794221 · DOI 10.3390/ph17050652
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer.
Liang Y, Zhang P, Li F, Lai H, et al · · 2023 · cited 10× · PMID 38352694 · DOI 10.3389/fphar.2023.1332539
Novel treatment approaches utilizing antibody-drug conjugates in breast cancer.
Davis AA, Hesse J, Pereira PMR, Ma CX. · · 2025 · cited 8× · PMID 40360516 · DOI 10.1038/s41523-025-00743-w
Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies.
Najdi T, Awad L, Chartouni A, Soueidy C, et al · · 2025 · cited 5× · PMID 40304863 · DOI 10.1007/s10637-025-01525-8
Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer.
Koukoutzeli C, Trapani D, Ascione L, Kotteas E, et al · · 2024 · cited 5× · PMID 38894701 · DOI 10.1177/11795549241260418

Verify or expand the search:

Other trials of Sacituzumab Govitecan

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07328490 — Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Trea · Phase 1, PHASE2 · not yet recruiting
NCT07368543 — Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer · Phase 2 · not yet recruiting
NCT06462092 — Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Canc · Phase 1, PHASE2 · recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05675579 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 4 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05675579.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing